Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Gains from Sales and Divestitures (2022 - 2025)

CytomX Therapeutics (CTMX) has disclosed Gains from Sales and Divestitures for 4 consecutive years, with $527238.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Gains from Sales and Divestitures rose 358.47% year-over-year to $527238.0, compared with a TTM value of $527238.0 through Sep 2025, up 358.47%, and an annual FY2024 reading of $733201.0, up 233.27% over the prior year.
  • Gains from Sales and Divestitures was $527238.0 for Q3 2025 at CytomX Therapeutics, up from $275000.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $733201.0 in Q4 2024 and bottomed at $110892.0 in Q1 2023.
  • Average Gains from Sales and Divestitures over 4 years is $380806.8, with a median of $323204.0 recorded in 2023.
  • Peak annual rise in Gains from Sales and Divestitures hit 537.49% in 2024, while the deepest fall reached 64.42% in 2024.
  • Year by year, Gains from Sales and Divestitures stood at $193750.0 in 2022, then grew by 13.55% to $220000.0 in 2023, then soared by 233.27% to $733201.0 in 2024, then fell by 28.09% to $527238.0 in 2025.
  • Business Quant data shows Gains from Sales and Divestitures for CTMX at $527238.0 in Q3 2025, $275000.0 in Q2 2025, and $521404.0 in Q1 2025.